Psychopharmacology Update 30
January 26 @ 9:00 am - 3:30 pm UTC-7
8:15 a.m. – Registration, Continental Breakfast, Booth Exhibits
8:55 a.m. – Opening Remarks
9:00 a.m. – Treatment of Obesity with Emphasis on Topics of Interest to Psychiatrists
Frank Greenway, M.D., Medical Director and Professor, Pennington Biomedical Research Center Baton Rouge, Louisiana
This talk will discuss the role played by the reward system compared to the hypothalamic hunger system by drugs approved for the treatment of obesity. We will discuss the cannabinoid system and potential approaches to treating obesity and avoiding the depression problems seen with cannabinoid-1 inverse agonists like rimonabant. Causing weight loss at the body locations people feel are problem areas as a way of improving self-image when losing weight will also be discussed.
10:15 a.m. – Break
10:30 a.m. – Neuromodulation: The Future of Treatment for Neuropsychiatric Illness
Andrew Leuchter, M.D., Professor of Psychiatry and Biobehavioral Sciences; Director, TMS Clinical and Research Service; Director, Neuromodulation Division.
Neuromodulation treatments are an emerging class of technologies that apply magnetic or electrical energy to the brain to treat depression, Obsessive-Compulsive Disorder, chronic pain, and other neuropsychiatric illnesses. Neuromodulation treatments can be used as either an alternative or an addition to medications for the treatment of illness. These cutting edge technologies modify the activity of neural networks, and include non-invasive methods that utilize electromagnets or small electrodes applied to the scalp, and invasive techniques that involve insertion of electrodes into the brain. Non-invasive treatments include repetitive Transcranial Magnetic Stimulation (rTMS), Electroconvulsive Therapy (ECT), transcranial Direct Current Stimulation (tDCS), Trigeminal Nerve Stimulation (TNS), and synchronized Transcranial Magnetic Stimulation (sTMS). Invasive techniques include Deep Brain Stimulation (DBS) and Vagal Nerve Stimulation (VNS). These techniques offer new hope for the the treatment of patients who have received inadequate benefit from medications. This talk will review the effectiveness of neuromodulation treatments that currently are available, as well as major experimental treatments in development.
11:45 a.m. – Lunch Break (on our own)
1:00 p.m. – An Update on Anxiety Disorders
Mark H. Pollack, M.D., The Grainger Professor and Chairman, Department of Psychiatry, Rush University Medical Center.
This talk will review pharmacologic strategies to improve the outcomes for treatment of individuals with anxiety disorders.
2:15 p.m. – The Top Ten Drug Interactions that Limit Efficacy in Psychiatric Treatment
Paul Zarkowski, M.D., Clinical Assistant Professor, Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, University of Washington; Psychiatrist, Sound, Seattle, Washington.
Although there are numerous resources to guide prescribers away from harmful drug interactions and pharmacokinetic interactions, there is less written on interactions that limit efficacy. These are common and can be grouped in three categories including functional drug interactions with opposing functions and side effect profiles, drug interactions with antagonistic mechanisms of action and controversial drug interactions with opposing pharmacology. Each of these categories is represented in the top ten drug interactions that limit efficacy. The relative prevalence of each efficacy limiting interaction will be presented and discussed.
SCPS Member – $200.00
Non-SCPS Member – $225.00
SCPS Resident* – $30.00
Non-SCPS Resident* – $40.00
Register via Paypal
Above fees effective until 1/15. After 1/15 and at-door registrations additional $25.
*Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. with registration form. NO EXCEPTIONS.
To Register with a check, please print – this brochure – and mail payment to: SCPS, 2999 Overland Ave. Suite 208, Los Angeles, CA. 90064
Cancellations must be received 48 hours prior to the meeting and will be assessed a $45 administrative processing fee.
SCPS would like to thank: Michael Gales, M.D. (Program Chair), David Fogelson, M.D., Jacquelyn Green, M.D., Samuel Miles, M.D., and Heather Silverman, M.D. for planning this event.
5 Hours Category 1 CME will be available for this meeting.
The Southern California Psychiatric Society (SCPS) is accredited by the Institute of Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. SCPS takes responsibility for the content, quality and scientific integrity of this CME activity.
SCPS designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.